Business
SeaStar Medical Announces Publication of Clinical Trial Results Demonstrating its SCD Significantly Lowered Mortality Rates among Critically Ill ICU COVID-19 Patients by Safely and Effectively Stopping Inflammation Causing Cytokine Storms
Results published in the Society of Critical Care Management’s journal, Critical Care Explorations DENVER, CO and TAMPA, FL, June 07, 2022 (GLOBE NEWSWIRE) --
About this update from Seastar Medical Holding Corporation
[{"type":"text","content":"Results published in the Society of Critical Care Management’s journal, Critical Care Explorations\nDENVER, CO and TAMPA, FL, June 07, 2022 (GLOBE NEWSWIRE) -- SeaStar Medical, a medical technology company developing a platform therapy to reduce the consequences of hyperinflammation on vital organs, and LMF Acquisition Opportunities, Inc. (NASDAQ: LMAO) (LMAO), a special purpose acquisition company, today announced the publication of results from SeaStar Medical’s pilot SCD 005 clinical study to evaluate the safety and clinical outcomes of extracorporeal immunomodulation treatment with SeaStar Medical’s Selective Cytopheretic Device (SCD) in COVID-19 patients with multiple organ failure in the intensive care unit (ICU). The article, \"Extracorporeal Immunomodulation Treatment and Clinical Outcomes in ICU COVID-19 Patients,\" was published in the May 2022 issue of the Society of Critical Care Medicine’s (SCCM) Critical Care Explorations. “The study met its primary endpoints, and the results published in Critical Care Explorations are an important step in validating the role neutrophils and monocytes play as the effector cells responsible for a dysregulated systemic inflammatory response. By removing the most activated neutrophils and monocytes from circulation, the SCD's immunomodulatory impact enables a return to a regulated healing process,” said Dr. H. David Humes, professor of nephrology at University of Michigan, one of the lead investigators of the study and a director of SeaStar Medical. Mortality rates are high among intensive care patients with COVID-19 and acute kidney injury (AKI) requiring continuous renal replacement therapy (CRRT) and/or acute respiratory distress syndrome (ARDS) on mechanical ventilation. In this study of 22 patients, the SCD was integrated into the CRRT blood circuit with strictly controlled low ionized calcium concentration between 0.25 and 0.4 mmol/L achieved using regional citrate anticoagulation and calcium-free dialysate. Patients were treated for up to 10 days. The SCD was changed every 24 hours or as needed. Patients experienced reductions in activated neutrophils and monocytes, which led to reduction in proinflammatory cytokines and improved clinical outcomes. SCD-treated subjects had a reduction in 60-day mortality to 50% compared with 81% in the control cohort. The subjects who received ...